Balovaptan
Balovaptan, also known as RG7314, is a vasopressin receptor antagonist. Balovaptan has shown potential as a treatment for people with autism spectrum disorder (ASD). Balovaptan has shown the potential to improve social interaction and communication in people with ASD. Balovaptan is an investigational small molecule currently in clinical development by Roche for the treatment of ASD. It acts as a vasopressin (V1a) receptor antagonist.
| Supplier | Ace Therapeutics |
|---|---|
| Product # | SMD450 |
| CAS # | 1228088-30-9 |
| Pricing | Customizable size, Inquiry |
| Synonym | RG7314; RG 7314; RG-7314; Balovaptan |
| Product Category | Lab-use Small Molecule Drugs |
| Chemical Formula | C22H24ClN5O |
| Exact Mass | 409.1669 |
| Molecular Weight | 409.918 |
| Elemental Analysis | C, 64.46; H, 5.90; Cl, 8.65; N, 17.09; O, 3.90 |
| IUPAC/Chemical Name | 8-chloro-5-methyl-1-{trans-4-[(pyridin-2-yl)oxy]cyclohexyl}-5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine |
| InChi Key | GMPZPHGHNDMRKL-RZDIXWSQSA-N |
| InChi Code | InChI=1S/C22H24ClN5O/c1-27-13-16-12-17(23)7-10-19(16)28-20(14-27)25-26-22(28)15-5-8-18(9-6-15)29-21-4-2-3-11-24-21/h2-4,7,10-12,15,18H,5-6,8-9,13-14H2,1H3/t15-,18- |
| SMILES Code | CN1CC2=NN=C([C@H]3CC[C@H](OC4=NC=CC=C4)CC3)[N@]2[C@]5=CC=C(Cl)C=C5C1 |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Shelf Life | >2 years if stored properly |
| Drug Formulation | This drug may be formulated in DMSO |
| Stock Solution Storage | 0 - 4℃ for short term (days to weeks), or -20℃ for long term (months). |
| HS Tariff Code | 2934.99.9001 |